12.19.13
Siemens Healthcare Diagnostics Inc., based in Tarrytown, N.Y., is collaborating with pharmaceutical giant Pfizer Inc. to develop diagnostic tests for therapeutic products across Pfizer’s pipeline. Under the agreement, Siemens will be one of Pfizer’s collaboration partners to develop in-vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.
The partnership will leverage Siemens’ worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development.
“Companion diagnostics are an important enabler of targeted therapies for patients,” said John Hubbard, senior vice president and worldwide head of development operations at Pfizer. “This agreement … is another example of Pfizer’s commitment to develop new precision medicines to address unmet clinical needs.”
Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
“Our relationship with Pfizer marks a major milestone in Siemens’ personalized medicine strategy,” said Trevor Hawkins, senior vice president of strategy and innovations for the diagnostics division of Siemens Healthcare. “We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and, together, shape the future of diagnostic medicine.”
Siemens’ healthcare division is one of the world's largest medtech firms, specializing in medical imaging, laboratory diagnostics and medical information technology and hearing aids. Parent company Siemens, based in Munich, Germany, is a multinational conglomerate serving a number of different industries.
Founded in Brooklyn, N.Y., in 1849, Pfizer remains headquartered in New York City.
The partnership will leverage Siemens’ worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development.
“Companion diagnostics are an important enabler of targeted therapies for patients,” said John Hubbard, senior vice president and worldwide head of development operations at Pfizer. “This agreement … is another example of Pfizer’s commitment to develop new precision medicines to address unmet clinical needs.”
Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
“Our relationship with Pfizer marks a major milestone in Siemens’ personalized medicine strategy,” said Trevor Hawkins, senior vice president of strategy and innovations for the diagnostics division of Siemens Healthcare. “We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and, together, shape the future of diagnostic medicine.”
Siemens’ healthcare division is one of the world's largest medtech firms, specializing in medical imaging, laboratory diagnostics and medical information technology and hearing aids. Parent company Siemens, based in Munich, Germany, is a multinational conglomerate serving a number of different industries.
Founded in Brooklyn, N.Y., in 1849, Pfizer remains headquartered in New York City.